Recent figures from Ireland on the effect of the patent
cliff are a timely reminder to CIPOs to look again at their
internal practices to ameliorate the possible effect of their
companies' own patent cliffs
The effect of the pharmaceutical patent1 cliff is
still evident around the world, with the latest fall-out cited in
new figures from the Irish Exporters Association. A contraction in
the Irish merchandise sector of €2.9 billion is mainly
attributed to the loss of pharmaceutical exports and coincides with
Pzifer's Viagra– the main ingredients of which are made
in Cork – coming off patent.
As anyone in R&D knows, you cannot necessarily force the
development of breakthrough compounds such as Lipitor, Viagra or
Roundup. But IP2 counsel can put practices in place to
lessen the revenue drop which occurs when a major product is out of
patent.